Diuretics in monotherapy and in combination with other diuretics and non‑diuretics in the treatment of hypertension

Czech version

Authors: J. Špinar ¹; L. Špinarová ²; J. Vítovec ²
Authors‘ workplace: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jindřich Špinar, CSc., FESC ¹; I. interní kardio‑angiologická klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednostka prof. MU Dr. Lenka Špinarová, Ph. D., FESC ²
Published in: Vnitř Lék 2013; 59(6): 486-494
Category: 80th birthday prof. MUDr. Karla Horkého, DrSc., FACP (Hon.)

Overview

Diuretics belong to the basic group of medicines for the treatment of hypertension and heart failure. In the case of hypertension treatment, their main indication is higher age and isolated systolic hypertension. In the case of heart failure they are used for the treatment of swellings and shortness of breath. The most frequently prescribed group of diuretics is thiazides and similar products. In patients with renal insufficiency, loop diuretics are administered. In the case of hypertension, diuretics are mainly used in the combination treatment. The most frequently used diuretic in combination is again hydrochlorothiazide, which is combined with renin‑angiotensin system blockers. It is mainly the combination of an ACE inhibitor + indapamide that seems to be modern and promising, and it is, on the basis of large clinical trials, recommended also for diabetics (ADVANCE) or for secondary prevention following a cerebrovascular accident (PROGRESS) or for the elderly (HYVET). Also a combination of two diuretics is popular – mainly hydrochlorothiazide + amiloride. A combination of a beta‑blocker and diuretic is less suitable.

Key words:
diuretics – hypertension – monotherapy – combination

Sources

1. Vítovec J, Špinar J. Farmakoterapie kardiovaskulárních onemocnění. Praha: Grada 2004.

2. Filipovský J, Widimský J jr., Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Hypertenz Kardiovaskul Prev 2012; 3: 1– 16.

3. Filipovský J, Widimský J jr., Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58: 785– 801.

4. Cífková R, Škodová Z, Bruthans J et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/ 2008. J Hypertens 2010; 28: 2196– 2203.

5. Špinar J, Vítovec J, Zicha J. Hypertenze – diagnostika a léčba. Praha: Grada 1999.

6. Cobanian AV, Bakris BL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560– 2572.

7. Williams B, Poulter NR, Brown JM et al. British Hypertension Society guidelines for hypertension management 2004 (BHS‑ IV). BMJ 2004; 328: 634– 640.

8. Mancia G, Laurent S, Agabiti‑ Rosei L et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009; 27: 2121– 2158.

9. Task Force Members 2007. Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105– 1187.

10. Stop hypertension 2 investigators: Stop hypertension 2. Lancet 1999; 354: 1751– 1756.

11. MRC investigators. Medical Research Council Trial of Treatment of Hypertension in Oleder Adults. Br Med J 1992; 304: 405– 412.

12. The SHEP investigators. Systolic Hypertension in the Elderly Program Prevention of strokeby antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255– 3264.

13. Dhalla IA, Gomes T, Yao Y et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in Older Adults. A population based cohort study. Ann Intern Med 2013; 158: 447– 455.

14. Messerli F. Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT). Circulation 1990; 82: 616.

15. Dorsch MP, Gillespie BW, Erickson SR et al. Chlorthalidone Reduces Cardiovascular Events Compared With Hydrochlorothiazide. Hypertension 2011; 57: 689– 694.

16. Messerli FH, Makani H, Benjo A et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta‑analysis of randomized trials. JACC 2011; 57: 590– 600.

17. Ernst ME, Carter BL, Goerdt CJ et al. Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure. Hypertension 2006; 47: 352– 358.

18. Špinar J, Vítovec J. Vývoj doporučení pro léčbu hypertenze. Vnitř Lék 2005; 51: 75– 82.

19. Špinar J, Vítovec J. Kombinační léčba hypertenze. Causa Subita 2012; 15: 10– 13.

20. Vytřísalová M. Fixní kombinace v léčbě hypertenze. Remedia 2010; 20: 235– 239.

21. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed‑dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173– 1181.

22. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High‑Risk Patients. N Engl J Med 2008; 359: 2417– 2428.

23. Bakris G, Molitch M, Hewkin A et al. STAR Investigators. Differences in glucose tolerance between fixed‑dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592– 2597.

24. Dahlöf B, Devereux RB, Kjeldsen SE. LIFE investigators. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995– 1003.

25. Sato N, Saijo Y, Sasagawa Y et al. CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. J Hypertens 2013. In press.

26. Kronich IM, Woodward M, Sergie Z et al. Meta‑analysis: impact of drug class of adherence to antihypertensives. Circulation 2011; 123: 1611– 1621.

27. Verdechia P, Reboldi G, Angeli F et al. Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension 2004; 43: 963– 969.

28. Špinar J, Vítovec J, Hradec J et al. Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure 2011. Cor Vasa 2012; 54: E113– E134.

29. Vítovec J, Špinar J. Diuretika u srdečního selhání. Kapit Kardiol 2002; 4: 90– 92.

30. Widimský J et al. Hypertenze. 3. rozšířené a přepracované vydání. Praha: Triton 2008.

31. London G, Schmieder R, Calvo C et al. Indapamide SR versus candesartan and amlodipine in hypertension: the X‑ CELLENT Study. Am J Hypertens 2006; 19: 113– 121.

32. Asmar RG, London GM, O’Rourke ME et al.REASON Project coordinators and investigators. Improvement of blood pressure, arterial stiffness and wave reflections with a very‑ low‑dose perindopril/ indapamide combination in hypertensive patient, a comparison with atenolol. Hypertension 2001; 38: 922– 926.

33. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829– 840.

34. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887– 1898.

35. Vítovec J, Špinar J. Perindopril/ indapamid – fixní kombinace. Remedia 2007; 17: 247– 257.

36. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‑ Scandinavian Cardiac Outcomes Trial‑ Blood Pressure Lowering Arm (ASCOT‑ BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895– 906.

37. Poulter NR. ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rate noted in the Anglo‑ Scandinavian Cardiac Outcomes Trial‑ Blood Pressure Lowering Arm (ASCOT‑ BPLA). Lancet 2005; 366: 907– 913.

38. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed‑dose combinations improve medication compliance: a meta‑analysis. Am J Med 2007; 120: 713– 719.

39. Špinar J, Vítovec J, Špinarová L et al. Fixní kombinace v léčbě hypertenze. Vnitř Lék 2012; 58: 599– 607.